Canntab Therapeutics (CSE: PILL ) is pleased to announce the appointment of Bob Woloschuk to its Advisory Board. Bob has over 20 years of pharmaceutical executive experience and has a keen eye for licensing opportunities, both in Canada and in international markets. Jeff Renwick, Chief Executive Officer and a Director, commented "We are grateful for the opportunity to add someone of Bob's calibre to our Advisory Board, which already included some of the most impressive names in both capital markets, and cannabis research and development. Bob has a long history of successful business development within the key "Big Pharma" industry players, and has significant experience developing licensing strategies in the pharmaceutical industry. We look forward to working with Bob, who we believe adds tremendous value to our Advisory Board and the Company as a whole".